



You can definitely knock-out a gene but do you have what it takes in a battle? Who will be the next Contenders at AmorChem's KNOCK OUT™ Event? AmorChem invites you to throw your hat in the ring for a chance to participate in the 2017 edition of its KNOCK OUT Event.

Back by popular demand, AmorChem is hosting its fourth KNOCK OUT™ Event during the Lumira-AmorChem Event to be held in collaboration with the 11th edition of the Quebec City Healthcare Industry Forum on December 6th, 2017 in **Quebec City**. Researchers selected to participate in the Dragons' Den inspired AmorChem KNOCK OUT™ Event will fight it out in the ring against our panel of "heavyweights" eager to defend their title for the second year in a row.

If you are an academic life science researcher with an appetite to KNOCK OUT the competition, if you have innovative science with strong commercial potential, then you may be one of the participants chosen to duke it out in the AmorChem KNOCK OUT Event and could be granted an AmorChem financing of up to \$500,000!

Interested researchers must fill out the attached form describing their technology, its clinical applications, its relevance to human disease, as well as its commercial potential. As competition in the ring will be fierce, researchers are encouraged to seek the assistance of their technology transfer or commercialization office that can also prove useful in training for the final Event.

All application forms must be submitted no later than **Tuesday October 17th, 2017** at the following email address: info@amorchem.com

Participants chosen to climb into the ring in the final round will be notified no later than **Friday November 3rd, 2017**. They will then become Contenders in the Amorchem KNOCK OUT Event and will be invited to a call in order to assist them in their final preparations.

Contenders will then convene on December 6th, 2017 for the final round. The KNOCK OUT will play out in front of a live audience (last year was standing room only!). At the sound of the bell, each Contender will be given up to five minutes to make their case on their technology. Following their pitch, each Contender will duke it out, in the ring, with our "heavyweights" over a ten minute Q&A "boxing match". The Contenders will confront the "professional boxers" with only wits and scientific agility in their corner. Just as boxers climb into the ring with only their gloves, our contenders will not be allowed visual support.

The champion of this third edition of the AmorChem KNOCK OUT Event may qualify for a financing of up to \$500,000 from AmorChem, subject to completion of final pre-investment conditions including approval by the AmorChem Investment Committee.

Can you roll with the punches, and go 5 rounds in the ring with our seasoned biotech executives? If you think you can, act fast: spaces will be limited to a maximum of 5 participants and the deadline for application is Tuesday October 17th, 2017!

ABOUT AMORCHEM

AmorChem L.P. (www.amorchem.com) is a venture capital fund located in Montreal focused on creating promising life science companies from projects originating primarily from Quebec-based universities and research centres. Its principal limited partners are Investissement Québec, FIER Partenaires, Fonds de solidarité FTQ and Merck & Co. AmorChem's innovative business model involves financing and actively managing research-stage projects to enable them to reach a stage where they can attract new financial and pharma partners. In order to add value to the projects involving small molecules, AmorChem created NuChem Therapeutics Inc., a medicinal chemistry service provider.

AmorChem I has built a 24-project portfolio across innovative technologies and covering a large breadth of indications. To date, two projects have been the subject of successful transactions with pharma, most notably the sale of a cystic fibrosis project to Vertex Pharmaceuticals. In addition, five spin-off companies have been created (SemaThera inc., Corbin Therapeutics Inc., Mperia Therapeutics Inc., SpecificiT Pharma Inc. and Eosinate Therapeutics Inc.)

ABOUT NUCHEM THERAPEUTICS:

www.nuchemtherapeutics.com